|Tested species reactivity||Human|
|Published species reactivity||Human, Not Applicable, Rhesus monkey|
|Host / Isotype||Mouse / IgG2b|
|Immunogen||Activated human peripheral blood mononuclear cells.|
|Storage buffer||tissue culture supernatant with 0.7% BSA|
|Contains||0.1% sodium azide|
|Storage Conditions||4° C|
|Tested Applications||Dilution *|
|Immunohistochemistry (Paraffin) (IHC (P))||Assay dependent.|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
HLA DR, like other MHC class II molecules, is a transmembrane glycoprotein composed of an alpha chain (36 kDa) and a beta chain (27 kDa). It is expressed primarily on antigen presenting cells such as B lymphocytes, monocytes, macrophages, thymic epithelial cells and activated T lymphocytes. Three loci, DR, DQ and DP, encode the major expressed products of the human class II region. The human MHC class II molecules bind intracellularly processed peptides and present them to T-helper cells. They therefore have a critical role in the initiation of the immune response.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
SUCLG2 identified as both a determinator of CSF Aß1-42 levels and an attenuator of cognitive decline in Alzheimer's disease.
MA1-35420 was used in immunohistochemistry - paraffin section to discuss a meta-analysis of genome-wide association study data on Abeta1-42 and pTau181 in Alzheimer's disease dementia patients
|Ramirez A,van der Flier WM,Herold C,Ramonet D,Heilmann S,Lewczuk P,Popp J,Lacour A,Drichel D,Louwersheimer E,Kummer MP,Cruchaga C,Hoffmann P,Teunissen C,Holstege H,Kornhuber J,Peters O,Naj AC,Chouraki V,Bellenguez C,Gerrish A,Heun R,Frölich L,Hüll M,Buscemi L,Herms S,Kölsch H,Scheltens P,Breteler MM,Rüther E,Wiltfang J,Goate A,Jessen F,Maier W,Heneka MT,Becker T,Nöthen MM||Human molecular genetics (23:6644)||2014|
Tissue specificity of decellularized rhesus monkey kidney and lung scaffolds.
MA1-35420 was used in immunohistochemistry - paraffin section to optimize rhesus monkey decellularized kidney scaffolds
|Nakayama KH,Lee CC,Batchelder CA,Tarantal AF||PloS one (8:null)||2013|
Appearance of tissue transglutaminase in astrocytes in multiple sclerosis lesions: a role in cell adhesion and migration?
MA1-35420 was used in immunohistochemistry to investigate the role of tissue transglutaminase in astrocytes in multiple sclerosis lesions
|van Strien ME,Drukarch B,Bol JG,van der Valk P,van Horssen J,Gerritsen WH,Breve JJ,van Dam AM||Brain pathology (Zurich, Switzerland) (21:44)||2011|
Endometrial atypical hyperplasia with clear cell change spreading throughout the endometrium.
MA1-35420 was used in immunohistochemistry to report on a case of endometrial atypical hyperplasia with clear cell change spreading throughout the endometrium
|Nakashima N,Nagasaka T,Murakami S,Fukatsu T,Satake T||Annals of diagnostic pathology (7:381)||2003|
Dynamics of immune granuloma formation in a Leishmania braziliensis-induced self-limiting cutaneous infection in the primate Macaca mulatta.
MA1-35420 was used in flow cytometry and immunohistochemistry (paraffin) to study the host inflammatory granulomatous response that controls cutaneous leishmaniasis using a macaque model.
|Souza-Lemos C,de-Campos SN,Teva A,Côrte-Real S,Fonseca EC,Porrozzi R,Grimaldi G||The Journal of pathology (216:375)||2008|
Human macrophage lectin specific for galactose/N-acetylgalactosamine is a marker for cells at an intermediate stage in their differentiation from monocytes into macrophages.
MA1-35420 was used in flow cytometry and immunohistochemistry (frozen) to determine the expression of a human macrophage lectin specific for galactose/N-acetylgalactosamine during macrophage differentiation.
|Higashi N,Morikawa A,Fujioka K,Fujita Y,Sano Y,Miyata-Takeuchi M,Suzuki N,Irimura T||International immunology (14:545)||2002|
Identification of new MHC-restriction elements for presentation of the p210(BCR-ABL) fusion region to human cytotoxic T lymphocytes.
MA1-35420 was used in blocking or activating experiment to investigate the immune response against the p210(BCR-ABL) fusion region in chronic myelogenous leukemia
|Sun JY,Senitzer D,Forman SJ,Chatterjee S,Wong KK||Cancer immunology, immunotherapy : CII (52:761)||2003|